NewEdge Wealth’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-21,364
| Closed | -$3.22M | – | 973 |
|
|
2025
Q1 | $3.22M | Buy |
21,364
+4,403
| +26% | +$663K | 0.06% | 253 |
|
|
2024
Q4 | $3.13M | Sell |
16,961
-4,531
| -21% | -$836K | 0.05% | 264 |
|
|
2024
Q3 | $4.23M | Buy |
21,492
+1,135
| +6% | +$224K | 0.08% | 221 |
|
|
2024
Q2 | $4.21M | Buy |
20,357
+234
| +1% | +$48.3K | 0.09% | 190 |
|
|
2024
Q1 | $4.63M | Buy |
20,123
+1,927
| +11% | +$443K | 0.1% | 176 |
|
|
2023
Q4 | $4.3M | Buy |
18,196
+1,301
| +8% | +$308K | 0.11% | 159 |
|
|
2023
Q3 | $3.31M | Buy |
16,895
+1,524
| +10% | +$299K | 0.1% | 174 |
|
|
2023
Q2 | $3.23M | Buy |
15,371
+615
| +4% | +$129K | 0.11% | 180 |
|
|
2023
Q1 | $2.98M | Buy |
14,756
+584
| +4% | +$118K | 0.11% | 170 |
|
|
2022
Q4 | $3.09M | Buy |
14,172
+50
| +0.4% | +$10.9K | 0.13% | 146 |
|
|
2022
Q3 | $2.78M | Buy |
14,122
+921
| +7% | +$181K | 0.13% | 150 |
|
|
2022
Q2 | $2.83M | Buy |
13,201
+5,273
| +67% | +$1.13M | 0.13% | 145 |
|
|
2022
Q1 | $2.25M | Buy |
7,928
+1,357
| +21% | +$385K | 0.1% | 144 |
|
|
2021
Q4 | $2.48M | Buy |
6,571
+173
| +3% | +$65.2K | 0.1% | 148 |
|
|
2021
Q3 | $2.64M | Buy |
6,398
+881
| +16% | +$364K | 0.16% | 113 |
|
|
2021
Q2 | $2.04M | Buy |
5,517
+183
| +3% | +$67.7K | 0.16% | 125 |
|
|
2021
Q1 | $1.55M | Buy |
5,334
+4,450
| +503% | +$1.29M | 0.15% | 122 |
|
|
2020
Q4 | $221K | Buy |
+884
| New | +$221K | 0.07% | 139 |
|